lifestyle.fairytaleinkbooks.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Medicus Pharma Ltd
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
April 27, 2026
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
April 17, 2026
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
April 15, 2026
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
April 6, 2026
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
April 1, 2026
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
March 30, 2026
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
March 28, 2026
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
March 26, 2026
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
March 18, 2026
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
March 16, 2026
1
2
3
Next Page
→